<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00052221</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000069409</org_study_id>
    <secondary_id>MDA-DM-02331</secondary_id>
    <secondary_id>MDA-DM-0038</secondary_id>
    <secondary_id>NCI-P02-0225</secondary_id>
    <secondary_id>DM02-331</secondary_id>
    <nct_id>NCT00052221</nct_id>
    <nct_alias>NCT00563719</nct_alias>
  </id_info>
  <brief_title>Epoetin Alfa in Treating Fatigue in Patients With Advanced Solid Tumors Who Are Not Receiving Chemotherapy</brief_title>
  <official_title>A Placebo Controlled Trial Of Short-Term, High-Dose Epoetin Alfa In Advanced Cancer Outpatients With Mild Fatigue</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Epoetin alfa may help improve energy levels and quality of life in patients who&#xD;
      have advanced solid tumors.&#xD;
&#xD;
      PURPOSE: Randomized clinical trial to study the effectiveness of epoetin alfa in treating&#xD;
      fatigue in patients who are not receiving chemotherapy for advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the efficacy of epoetin alfa in treating fatigue in patients with advanced&#xD;
           solid tumors who are not receiving chemotherapy.&#xD;
&#xD;
        -  Determine the efficacy of this drug on functional status and overall quality of life in&#xD;
           these patients.&#xD;
&#xD;
        -  Correlate self-reported level of energy with other commonly occurring symptoms (e.g.,&#xD;
           pain, depression, anxiety, dyspnea, appetite disturbance, or sleep disturbance) in these&#xD;
           patients.&#xD;
&#xD;
        -  Correlate anemia with other common symptoms in these patients.&#xD;
&#xD;
        -  Determine the internal consistency of fatigue self-report using three single-item&#xD;
           measures of this symptom and the responsiveness of each item to change over time in&#xD;
           these patients.&#xD;
&#xD;
      OUTLINE: This is a double-blind, placebo-controlled, randomized, multicenter study. Patients&#xD;
      are stratified according to participating center, ECOG performance status (0-1 vs 2-3), and&#xD;
      hemoglobin prior to study (10 mg/dL or less vs greater than10 mg/dL). Patients are randomized&#xD;
      to one of two treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive epoetin alfa subcutaneously (SC) once weekly for 6 weeks.&#xD;
&#xD;
        -  Arm II: Patients receive placebo SC once weekly for 6 weeks. Patients in either arm that&#xD;
           do not respond to therapy may receive an additional 6 weeks of open-label epoetin alfa&#xD;
           SC once weekly.&#xD;
&#xD;
      In both arms, quality of life and fatigue are assessed at baseline and at 3 and 6 weeks. If&#xD;
      patients receive an additional 6 weeks of therapy, quality of life and fatigue are also&#xD;
      assessed at 9 and 12 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 128 patients (64 per treatment arm) will be accrued for this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">May 20, 2003</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Fatigue</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <arm_group>
    <arm_group_label>Arm I: Epoetin Alfa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Epoetin alfa subcutaneously (SC) once weekly for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm II: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneously (SC) once weekly for 6 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Epoetin alfa</intervention_name>
    <arm_group_label>Arm I: Epoetin Alfa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Arm II: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Diagnosis of stage III or IV invasive non-myeloid malignancy&#xD;
&#xD;
          -  Not currently hospitalized&#xD;
&#xD;
          -  At least somewhat bothered by fatigue based on self-report&#xD;
&#xD;
               -  No significant psychological distress indicated by total score of 6 or more on&#xD;
                  questions 1 and 2 of the Three-Question Screening Survey (3QSS)&#xD;
&#xD;
               -  No score less than 2 on question 3 of 3QSS indicating low level of fatigue within&#xD;
                  the past week&#xD;
&#xD;
          -  No uncontrolled brain metastases or leptomeningeal involvement&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) 0-3&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  At least 12 weeks&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Hemoglobin at least 8.5 g/dL but no greater than 11 g/dL&#xD;
&#xD;
          -  No anemia due to factors other than cancer or chemotherapy (e.g., iron or folate&#xD;
             deficiency, hemolysis, or bleeding)&#xD;
&#xD;
          -  No prior or concurrent hematological disease&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Cardiovascular:&#xD;
&#xD;
          -  No uncontrolled hypertension (diastolic blood pressure greater than 100 mm Hg or&#xD;
             systolic blood pressure greater than 200 mm Hg)&#xD;
&#xD;
          -  No significant uncontrolled concurrent cardiovascular disease or dysfunction not&#xD;
             attributable to malignancy or chemotherapy&#xD;
&#xD;
          -  No history of deep-vein thrombosis&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  No significant uncontrolled concurrent pulmonary disease or dysfunction not&#xD;
             attributable to malignancy or chemotherapy&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  Able to understand and complete self-report symptom assessment forms in English&#xD;
&#xD;
          -  No serious concurrent infection&#xD;
&#xD;
          -  No known hypersensitivity to mammalian cell-derived products or human albumin&#xD;
&#xD;
          -  No uncontrolled seizures&#xD;
&#xD;
          -  No significant uncontrolled concurrent endocrine, neurologic, gastrointestinal, or&#xD;
             genitourinary system disease or dysfunction not attributable to malignancy or&#xD;
             chemotherapy&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy (e.g., interferon or interleukin-2)&#xD;
&#xD;
          -  More than 2 months since prior red blood cells (RBC) transfusion&#xD;
&#xD;
          -  More than 1 month since prior epoetin alfa or investigational forms of epoetin alfa&#xD;
             (e.g., gene-activated, novel erythropoiesis-stimulating protein)&#xD;
&#xD;
          -  Concurrent non-myelosuppressive therapy (e.g., monoclonal antibody infusions,&#xD;
             antiangiogenesis inhibitors, or signal transduction inhibitors) allowed&#xD;
&#xD;
          -  No other concurrent biologic therapy&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  No prior high-dose chemotherapy (e.g., with bone marrow or stem cell transplantation)&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  Concurrent hormonal therapy allowed (e.g., luteinizing hormone-releasing hormone&#xD;
             agonists or tamoxifen)&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J. Fisch, MD, MPH, FACP</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>January 24, 2003</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>November 7, 2018</last_update_submitted>
  <last_update_submitted_qc>November 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>fatigue</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatigue</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

